Search

Your search keyword '"Máiz, Luis"' showing total 139 results
Start Over Author "Máiz, Luis" Publication Type Academic Journals
139 results on '"Máiz, Luis"'

2. C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON)

Author

Rolon, Annie Navarro, Minguez, Patricia, Amaro, Rosanel, Cervera, Angela, Blanco, Marina, Gomez, Ainhoa, Llorca, Eleuterio, Padilla, Alicia, Rosales, Edmundo, Carrasco, Laura, Razquin, Marcelo, Posadas, Tomás, Oscullo, Grace, Zaldivar, Enrique, Villa, Carmen, Dobarganes, Yadira, Girón, Rosa, Olveira, Casilda, Maíz, Luis, García-Clemente, Marta, Sibila, Oriol, Golpe, Rafael, Rodríguez, Juan, Barreiro, Esther, Rodriguez, Juan Luis, Menéndez, Rosario, Prados, Concepción, de la Rosa, David, and Martinez-García, Miguel Angel

Published
2021
Full Text
View/download PDF

7. Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study “MFIP”

Author

Delhaes, Laurence, Touati, Kada, Faure-Cognet, Odile, Cornet, Muriel, Botterel, Françoise, Dannaoui, Eric, Morio, Florent, Le Pape, Patrice, Grenouillet, Fréderic, Favennec, Loic, Le Gal, Solène, Nevez, Gilles, Duhamel, Alain, Borman, Andrew, Saegeman, Veroniek, Lagrou, Katrien, Gomez, Elia, Carro, Maiz-Luis, Canton, Rafael, Campana, Silvia, Buzina, Walter, Chen, Sharon, Meyer, Wieland, Roilides, Emmanuel, Simitsopoulou, Maria, Manso, Esther, Cariani, Lisa, Biffi, Arianna, Fiscarelli, Ersilia, Ricciotti, Gabriella, Pihet, Marc, and Bouchara, Jean-Philippe

Published
2019
Full Text
View/download PDF

8. Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience

Author

Diab-Cáceres, Layla, Girón-Moreno, Rosa María, Pastor-Sanz, María Teresa, Quintana-Gallego, Esther, Delgado-Pecellín, Isabel, Blanco-Aparicio, Marina, Maiz, Luis, García-Clemente, Marta María, Luna-Paredes, Carmen, Mondéjar-López, Pedro, Ruiz-de-Valbuena, Marta, Fernández, Ofelia, Barrio, Maribel, González, Maribel, López-Neyra, Alejandro, Cols-i-Roig, María, Palou-Rotger, Alexandre, and Gómez-de-Terreros-Caro, Francisco Javier

Published
2018
Full Text
View/download PDF

13. Prediction of the intestinal resistome by a three-dimensional structure-based method

Author

Ruppé, Etienne, Ghozlane, Amine, Tap, Julien, Pons, Nicolas, Alvarez, Anne-Sophie, Maziers, Nicolas, Cuesta, Trinidad, Hernando-Amado, Sara, Clares, Irene, Martínez, Jose Luís, Coque, Teresa M., Baquero, Fernando, Lanza, Val F., Máiz, Luis, Goulenok, Tiphaine, de Lastours, Victoire, Amor, Nawal, Fantin, Bruno, Wieder, Ingrid, Andremont, Antoine, van Schaik, Willem, Rogers, Malbert, Zhang, Xinglin, Willems, Rob J. L., de Brevern, Alexandre G., Batto, Jean-Michel, Blottière, Hervé M., Léonard, Pierre, Léjard, Véronique, Letur, Aline, Levenez, Florence, Weiszer, Kevin, Haimet, Florence, Doré, Joël, Kennedy, Sean P., and Ehrlich, S. Dusko

Published
2019
Full Text
View/download PDF

14. Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study

Author

López-Causapé, Carla, de Dios-Caballero, Juan, Cobo, Marta, Escribano, Amparo, Asensio, Óscar, Oliver, Antonio, del Campo, Rosa, Cantón, Rafael, Solé, Amparó, Cortell, Isidoro, Asensio, Oscar, García, Gloria, Martínez, María Teresa, Cols, María, Salcedo, Antonio, Vázquez, Carlos, Baranda, Félix, Girón, Rosa, Quintana, Esther, Delgado, Isabel, de Miguel, María Ángeles, García, Marta, Oliva, Concepción, Prados, María Concepción, Barrio, María Isabel, Pastor, María Dolores, Olveira, Casilda, de Gracia, Javier, Álvarez, Antonio, Castillo, Silvia, Figuerola, Joan, Togores, Bernat, López, Carla, de Dios Caballero, Juan, Tato, Marta, Máiz, Luis, and Suárez, Lucrecia

Published
2017
Full Text
View/download PDF

17. Bronchopulmonary infection–colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study

Author

Solé, Amparó, Cortell, Isidoro, Asensio, Oscar, García, Gloria, Martínez, María Teresa, Cols, María, Salcedo, Antonio, Vázquez, Carlos, Baranda, Félix, Girón, Rosa, Quintana, Esther, Delgado, Isabel, de Miguel, María Ángeles, García, Marta, Oliva, Concepción, Prados, María Concepción, Barrio, María Isabel, Pastor, María Dolores, Olveira, Casilda, de Gracia, Javier, Álvarez, Antonio, Escribano, Amparo, Castillo, Silvia, Figuerola, Joan, Togores, Bernat, Oliver, Antonio, López, Carla, de Dios Caballero, Juan, Tato, Marta, Máiz, Luis, Suárez, Lucrecia, Cantón, Rafael, del Campo, Rosa, Royuela, Ana, Solé, Amparo, Quintana-Gallego, Esther, Cobo, Marta, and de la Pedrosa, Elia Gómez G.

Published
2016
Full Text
View/download PDF

18. Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

Author

Cantón, Rafael, Máiz, Luis, Escribano, Amparo, Olveira, Casilda, Oliver, Antonio, Asensio, Oscar, Gartner, Silvia, Roma, Eva, Quintana-Gallego, Esther, Salcedo, Antonio, Girón, Rosa, Barrio, María Isabel, Pastor, María Dolores, Prados, Concepción, Martínez-Martínez, María Teresa, Barberán, José, Castón, Juan José, Martínez-Martínez, Luis, Poveda, José Luis, Vázquez, Carlos, de Gracia, Javier, and Solé, Amparo

Published
2015
Full Text
View/download PDF

19. Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística

Author

Cantón, Rafael, Máiz, Luis, Escribano, Amparo, Olveira, Casilda, Oliver, Antonio, Asensio, Oscar, Gartner, Silvia, Roma, Eva, Quintana-Gallego, Esther, Salcedo, Antonio, Girón, Rosa, Barrio, María Isabel, Pastor, María Dolores, Prados, Concepción, Martínez-Martínez, María Teresa, Barberán, José, Castón, Juan José, Martínez-Martínez, Luis, Poveda, José Luis, Vázquez, Carlos, de Gracia, Javier, and Solé, Amparo

Published
2015
Full Text
View/download PDF

25. Impact of Chronic Bronchial Infection by Staphylococcus aureus on Bronchiectasis.

Author

García Clemente, Marta, Olveira, Casilda, Girón, Rosa, Máiz, Luis, Sibila, Oriol, Golpe, Rafael, Menéndez, Rosario, Rodríguez, Juan, Barreiro, Esther, Rodríguez Hermosa, Juan Luis, Prados, Concepción, De la Rosa, David, Carbajal, Claudia Madrid, Solís, Marta, and Martínez-García, Miguel Ángel

Subjects
BRONCHIECTASIS, STAPHYLOCOCCUS aureus infections, PULMONARY function tests, MICROBIAL cultures
Abstract

The objective of the study was to analyze the factors associated with chronic bronchial infection (CBI) due to methicillin-susceptible Staphylococcus aureus (SA) and assess the clinical impact on severity, exacerbations, hospitalizations, and loss of lung function compared to patients with no isolation of PPMs in a large longitudinal series of patients from the Spanish bronchiectasis registry (RIBRON). Material and methods: A prospective, longitudinal, multicenter study was conducted with patients included in the RIBRON registry between January 2015 and October 2020. The inclusion criteria were an age of 18 years or older and an initial diagnosis of bronchiectasis. Patients recorded in the registry had a situation of clinical stability in the absence of an exacerbation in the four weeks before their inclusion. All patients were encouraged to provide a sputum sample at each visit for microbiological culture. Annual pulmonary function tests were performed according to the national spirometry guidelines. Results: A total of 426 patients were ultimately included in the study: 77 patients (18%) with CBI due to SA and 349 (82%) who did not present any isolation of PPMs in sputum. The mean age was 66.9 years (16.2), and patients 297 (69.7%) were female, with an average BMI of 25.1 (4.7) kg/m2 and an average Charlson index of 1.74 (1.33). The mean baseline value of FEV1 2 L was 0.76, with a mean FEV1% of 78.8% (23.1). One hundred and seventy-two patients (40.4%) had airflow obstruction with FEV1/FVC < 0.7. The mean predictive FACED score was 1.62 (1.41), with a mean value of 2.62 (2.07) for the EFACED score and 7.3 (4.5) for the BSI score. Patients with CBI caused by SA were younger (p < 0.0001), and they had a lower BMI (p = 0.024) and more exacerbations in the previous year (p = 0.019), as well as in the first, second, and third years of follow-up (p = 0.020, p = 0.001, and p = 0.018, respectively). As regards lung function, patients with CBI due to SA had lower levels of FEV1% at the time of inclusion in the registry (p = 0.021), and they presented more frequently with bronchial obstruction (p = 0.042). A lower age (OR: 0.97; 95% CI: 0.94–0.99; p < 0.001), lower FEV1 value% (OR: 0.98; 95% CI: 0.97–0.99; p = 0.035), higher number of affected lobes (OR: 1.53; 95% CI: 1.2–1.95; p < 0.001), and the presence of two or more exacerbations in the previous year (OR: 2.33; 95% CI: 1.15–4.69; p = 0.018) were observed as independent factors associated with CBI due to SA. The reduction in FEv1% in all patients included in the study was −0.31%/year (95% CI: −0.7; −0.07) (p = 0.110). When the reduction in FEv1% is analyzed in the group of patients with CBI due to SA and the group without pathogens, we observed that the reduction in FEV1% was −1.19% (95% CI: −2.09, −0.69) (p < 0.001) in the first group and −0.02% (95% CI: −0.07, −0.01) (p = 0.918) in the second group. According to a linear regression model (mixed effects) applied to determine which factors were associated with a more pronounced reduction in FEv1% in the overall group (including those with CBI due to SA and those with no PPM isolation), age (p = 0.0019), use of inhaled corticosteroids (p = 0.004), presence of CBI due to SA (p = 0.007), female gender (p < 0.001), and the initial value of FEV1 (p < 0.001) were significantly related. Conclusions: Patients with non-CF bronchiectasis with CBI due to SA were younger, with lower FEV1% values, more significant extension of bronchiectasis, and a higher number of exacerbations of mild to moderate symptoms than those with no PPM isolation in respiratory secretions. The reduction in FEV1% was −1.19% (95% CI: −2.09, −0.69) (p < 0.001) in patients with CBI caused by SA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Blood Neutrophil Counts Define Specific Clusters of Bronchiectasis Patients: A Hint to Differential Clinical Phenotypes.

Author

Wang, Xuejie, Olveira, Casilda, Girón, Rosa, García-Clemente, Marta, Máiz, Luis, Sibila, Oriol, Golpe, Rafael, Menéndez, Rosario, Rodríguez-López, Juan, Prados, Concepción, Martinez-García, Miguel Angel, Rodriguez, Juan Luis, de la Rosa, David, Qin, Liyun, Duran, Xavier, Garcia-Ojalvo, Jordi, and Barreiro, Esther

Subjects
BRONCHIECTASIS, NEUTROPHILS, MANN Whitney U Test, PHENOTYPES, NUTRITIONAL status
Abstract

We sought to investigate differential phenotypic characteristics according to neutrophil counts, using a biostatistics approach in a large-cohort study from the Spanish Online Bronchiectasis Registry (RIBRON). The 1034 patients who met the inclusion criteria were clustered into two groups on the basis of their blood neutrophil levels. Using the Mann–Whitney U test to explore potential differences according to FACED and EFACED scores between the two groups, a neutrophil count of 4990 cells/µL yielded the most balanced cluster sizes: (1) above-threshold (n = 337) and (2) below-threshold (n = 697) groups. Patients above the threshold showed significantly worse lung function parameters and nutritional status, while systemic inflammation levels were higher than in the below-threshold patients. In the latter group, the proportions of patients with mild disease were greater, while a more severe disease was present in the above-threshold patients. According to the blood neutrophil counts using biostatistics analyses, two distinct clinical phenotypes of stable patients with non-CF bronchiectasis were defined. Patients falling into the above-threshold cluster were more severe. Severity was characterized by a significantly impaired lung function parameters and nutritional status, and greater systemic inflammation. Phenotypic profiles of bronchiectasis patients are well defined as a result of the cluster analysis of combined systemic and respiratory variables. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.

Author

de Dios Caballero, Juan, Cantón, Rafael, Ponce-Alonso, Manuel, García-Clemente, Marta María, Gómez G. de la Pedrosa, Elia, López-Campos, José Luis, Máiz, Luis, del Campo, Rosa, and Martínez-García, Miguel Ángel

Subjects
RESPIRATORY diseases, CHRONIC diseases, CHRONIC obstructive pulmonary disease, MYCOPLASMA gallisepticum, LUNG diseases, NUCLEOTIDE sequencing, FUNGAL communities, PREMATURE infants
Abstract

Microbes play an important role in the pathogenesis of chronic lung diseases, such as chronic obstructive pulmonary disease, cystic fibrosis, non-cystic fibrosis bronchiectasis, and asthma. While the role of bacterial pathogens has been extensively studied, the contribution of fungal species to the pathogenesis of chronic lung diseases is much less understood. The recent introduction of next-generation sequencing techniques has revealed the existence of complex microbial lung communities in healthy individuals and patients with chronic respiratory disorders, with fungi being an important part of these communities' structure (mycobiome). There is growing evidence that the components of the lung mycobiome influence the clinical course of chronic respiratory diseases, not only by direct pathogenesis but also by interacting with bacterial species and with the host's physiology. In this article, we review the current knowledge on the role of fungi in chronic respiratory diseases, which was obtained by conventional culture and next-generation sequencing, highlighting the limitations of both techniques and exploring future research areas. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Fungi in Bronchiectasis: A Concise Review.

Author

Máiz, Luis, Nieto, Rosa, Cantón, Rafael, Gómez G. de la Pedrosa, Elia, and Martinez-García, Miguel Ángel

Subjects
*BRONCHIECTASIS, *BRONCHIAL diseases, *MYCOSES, *CANDIDA albicans, *ASPERGILLUS fumigatus, *HAEMOPHILUS influenzae, *PSEUDOMONAS aeruginosa
Abstract

Although the spectrumof fungal pathology has been studied extensively in immunosuppressed patients, little is known about the epidemiology, risk factors, and management of fungal infections in chronic pulmonary diseases like bronchiectasis. In bronchiectasis patients, deteriorated mucociliary clearance--generally due to prior colonization by bacterial pathogens--and thick mucosity propitiate, the persistence of fungal spores in the respiratory tract. The most prevalent fungi in these patients are Candida albicans and Aspergillus fumigatus; these are almost always isolated with bacterial pathogens like Haemophillus influenzae and Pseudomonas aeruginosa, making very difficult to define their clinical significance. Analysis of the mycobiome enables us to detect a greater diversity of microorganisms than with conventional cultures. The results have shown a reduced fungal diversity in most chronic respiratory diseases, and that this finding correlates with poorer lung function. Increased knowledge of both the mycobiome and the complex interactions between the fungal, viral, and bacterial microbiota, including mycobacteria, will further our understanding of the mycobiome's relationship with the pathogeny of bronchiectasis and the development of innovative therapies to combat it. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

43. Sex bias in diagnostic delay in bronchiectasis: An analysis of the Spanish Historical Registry of Bronchiectasis.

Author

Girón, Rosa Ma, de Gracia Roldán, Javier, Olveira, Casilda, Vendrell, Montserrat, Martínez-García, Miguel Ángel, de la Rosa, David, Máiz, Luis, Ancochea, Julio, Vázquez, Liliana, Borderías, Luis, Polverino, Eva, Martínez-Moragón, Eva, Rajas, Olga, and Soriano, Joan B.

Abstract

Diagnostic delay is common in most respiratory diseases, particularly in bronchiectasis. However, sex bias in diagnostic delay has not been studied to date. Objective: Assessment of diagnostic delay in bronchiectasis by sex. Methods: The Spanish Historical Registry of Bronchiectasis recruited adults diagnosed with bronchiectasis from 2002 to 2011 in 36 centres in Spain. From a total of 2113 patients registered we studied 2099, of whom 1125 (53.6%) were women. Results:No differences were found for sex or age (61.0±20.6, p=0.88) or for localization of bronchiectasis (p = 0.31). Bronchiectasis of unknown aetiology and secondary to asthma, childhood infections and tuberculosis was more common in women (all ps < 0.05). More men than women were chronic obstructive pulmonary disease-related bronchiectasis and colonized by Haemophilus influenzae (p < 0.001 for both). Onset of symptoms was earlier in women. The diagnostic delay for women with bronchiectasis was 2.1 yearsmore than for men (p = 0.001). Discussion: We recorded a substantial delay in the diagnosis of bronchiectasis. This delay was significantly longer in women than in men (>2 years). Independent factors associated with this sex bias were age at onset of symptoms, smoking history, daily expectoration and reduced lung function. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

48. Annual direct medical costs of bronchiectasis treatment.

Author

de la Rosa, David, Martínez-Garcia, Miguel-Angel, Olveira, Casilda, Girón, Rosa, Máiz, Luis, and Prados, Concepción

Abstract

Patients with bronchiectasis (BE) present exacerbations that increase with severity of the disease. We aimed to determine the annual cost of BE treatment according to its severity, determined by FACED score, as well as the parameters associated with higher costs. Multicentre historical cohorts study with patients from six hospitals in Spain. The costs arising during the course of a year from maintenance treatment, exacerbations, emergency visits and hospital admissions were analysed. In total, 456 patients were included (56.4% mild BE, 26.8% moderate BE and 16.9% severe BE). The mean cost was €4671.9 per patient, which increased significantly with severity. In mild BE, most of the costs were due to bronchodilators and inhaled steroids; in severe BE, most were due to exacerbations and inhaled antibiotics. Forced expiratory volume in 1 second (FEV1%), age, colonization by Pseudomonas aeruginosa and the number of admissions were independently related to higher costs. The highest costs were found in patients with BE associated with chronic obstructive pulmonary disease, with the most exacerbations and with chronic bronchial colonization by Pseudomonas aeruginosa (PA). In conclusion, BE patients gave rise to high annual costs, and these were doubled on each advance in severity on the FACED score. FEV1%, age, colonization by PA and the number of admissions were independently related to higher costs. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results